Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2024 Mar 21;13(6):1819. doi: 10.3390/jcm13061819

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© 2024 by the authors.

Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).

PMC Copyright notice

Response to brolucizumab therapy in a therapy-refractory patient with diabetic macular edema (DME) assessed by optical coherence tomography (OCT). Right eye of a 72-year-old woman with proliferative diabetic retinopathy (PDR) on fundus photography (upper left panel) and on fluorescein angiography (lower left panel) with intraretinal fluid (IRF) and disintegration of the external limiting membrane (ELM) on OCT (right panel). Previous intravitreal therapies were 6 injections of bevacizumab, 7 injections of aflibercept, and 4 dexamethasone implants before switching to brolucizumab. A resolved center-involving DME was seen after 3 injections q6w (week 18) and a complete regression of IRF after 4 injections q6w (week 24). The patient was extended to q12w (week 36) with a minimal recurrence of foveal IRF.